Forbes’ Bruce Japsen examined the LucyRx and Abarca Health combination as part of a broader PBM market shift. The article focuses on how the proposed deal could signal more merger and acquisition activity among PBMs as companies look for the operational scale needed to compete in a more demanding environment.
The coverage positions the combination as an example of where the market may be headed: independent PBMs building the size, technology and operating foundation to meet client and patient expectations while responding to increased scrutiny of the traditional PBM model. For LucyRx, the story reinforces a timely market reality: clients are looking for more choice, more accountability and a PBM relationship built for what comes next.
Share